The Chk1-mediated S-phase Checkpoint Targets Initiation Factor Cdc45 via a Cdc25A/Cdk2-Independent Mechanism

Peijun Liu¹, Laura R. Barkley¹, Tovah Day¹, Xiaohui Bi¹, Damien M. Slater¹, Mark G. Alexandrow², Heinz-Peter Nasheuer³, and Cyrus Vaziri¹*

Running Title: S-phase checkpoint regulation of Cdc45

From the ¹Department of Genetics and Genomics, Boston University School of Medicine, 715 Albany Street, Boston MA 02118, and ²H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, and ³National University of Ireland, Galway; Dept. of Biochemistry, Cell Cycle Control Laboratory; Galway; Ireland.

*To whom correspondence should be addressed: Tel: 617-638-4175; Fax: 617-414-1646; Email: cvaziri@bu.edu

DNA damage induced by the carcinogen Benzo[a]pyrene-Dihydrodiol Epoxide (BPDE) induces a Checkpoint kinase 1 (Chk1)-dependent S-phase checkpoint. Here we have investigated the molecular basis of BPDE-induced S-phase arrest. Chk1-dependent inhibition of DNA synthesis in BPDE-treated cells occurred without detectable changes in Cdc25A levels, Cdk2 activity or Cdc7-Dbf4 interaction. Over-expression studies showed that Cdc25A, Cyclin A-Cdk2 and Cdc7-Dbf4 are not rate-limiting for DNA synthesis when the BPDE-induced S-phase checkpoint is active. To investigate other potential targets of the S-phase checkpoint we tested the effects of BPDE on the chromatin-association of DNA replication factors. Levels of chromatin-associated Cdc45 (but not soluble Cdc45 levels) were reduced concomitant with BPDE-induced Chk1 activation and inhibition of DNA synthesis. The chromatin-association of Mcm7, Mcm10 and PCNA was unaffected by BPDE treatment. However, the association between Mcm7 and Cdc45 in the chromatin fraction was inhibited in BPDE-treated cells. ChIP analyses demonstrated reduced association of Cdc45 with the β-globin origin of replication in BPDE-treated cells. The inhibitory effects of BPDE on DNA synthesis, Cdc45-Mcm7 associations, and interactions between Cdc45 and the β-globin locus were abrogated by the Chk1 inhibitor UCN-01. Taken together, our results show that the association between Cdc45 and Mcm7 at origins of replication is negatively regulated by Chk1 in a Cdk2-independent manner. Therefore, Cdc45 is likely to be an important target of the Chk1-mediated S-phase checkpoint.

Cells are continuously exposed to endogenous and exogenous sources of DNA damage. Unrepaired DNA damage can cause mutations and therefore poses a serious threat to genome stability. Cells have evolved multiple mechanisms to minimize the detrimental effects of DNA damage. Cell cycle checkpoints are signal transduction pathways that respond to DNA damage by eliciting transient delays in the cell cycle (1). The resulting delays integrate DNA repair with cell cycle progression and are thought to be important for maintaining genomic stability. In response to genotoxins, the DNA damage response pathways prevent entry into S phase (the G1/S checkpoint), slow progression through S-phase (the intra-S or S phase checkpoint), and block entry into mitosis (the G2/M checkpoint) (1).

Components of checkpoint signaling pathways are highly conserved in eukaryotes. DNA damage is detected by sensors (e.g. ATR/ATRIP, 9-1-1 complex, ATM), with the aid of mediators (e.g. BRCA1, 53BP1, Claspin). Sensors act upstream of transducers (e.g. Chk1, Chk2) which in turn activate effectors (p53, Cdc25A) that interact with
cell cycle machinery to inhibit cell cycle progression (2).

The S-phase checkpoint downregulates initiation of DNA synthesis in response to DNA damage acquired during S-phase (3). We previously characterized an intra S-phase checkpoint elicited by the environmental carcinogen Benzo[a]pyrene (B[a]P) (4). B[a]P undergoes intracellular metabolism to generate the reactive species Benzopyrene Dihydrodiol Epoxide (BPDE) (5). BPDE reacts covalently with DNA to generate bulky adducts, mainly on the N2 position of deoxyguanosine residues (6,7). Different doses of BPDE inhibit DNA synthesis via distinct mechanisms. Low concentrations of BPDE (<100 nM) inhibit initiation of DNA synthesis transiently, yet do not affect elongation of existing replicons (8). Thus, the transient inhibition of DNA synthesis induced by <100 nM BPDE is an S-phase checkpoint that inhibits firing of origins of replication in response to DNA damage acquired during S-phase. We have shown that the checkpoint induced by low concentrations of BPDE is mediated via Chk1 and 9-1-1 pathways (4,9). Cells eventually recover from the S-phase checkpoint and low doses of BPDE do not affect cell viability (9). However, higher concentrations of BPDE (200-600 nM) inhibit initiation and elongation steps of DNA replication resulting in an irreversible block to DNA synthesis and loss of viability (8). The 9-1-1, Chk1 (and Chk2) pathways are strongly activated in response to 600 nM BPDE. However, the inhibition of DNA synthesis induced by 600 nM BPDE is not due to checkpoint signaling but instead results from global blocks to the progression of DNA polymerases by BPDE adducts (8).

The dose-dependent effects of BPDE on initiation and elongation are not unique to this agent. For instance UVC doses of <2.6 J/m² inhibit initiation of DNA synthesis without global effects on elongation (10) whereas higher doses inhibit both initiation and elongation. The inhibition of replication initiation by low doses of UVC requires ATR and Chk1 (11). Since many checkpoint studies using UVC are conducted with high doses (5-100 J/m²), it is not clear whether all the DNA damage signaling responses identified in such experiments are relevant to the S-phase checkpoint (i.e. inhibition of initiation) or if they represent responses to replication blocks (inhibition of elongation).

Downstream effectors of the Chk1-mediated S-phase checkpoint induced by bulky adducts (such as BPDE and UV-induced thymine dimers) have not been identified. However, the mechanism of the DNA double strand-break (DSB)-responsive S-phase checkpoint induced by Ionizing Radiation (IR) has been described in detail. There is considerable evidence that Cdc25A, a tyrosine phosphatase which contributes to the activation of Cyclin-dependent kinase 2 (Cdk2) (12), is targeted for degradation by IR-induced S-phase checkpoint signaling. IR-induced degradation of Cdc25A is thought to require the effector checkpoint kinases Chk1 and Chk2. Basal turnover of Cdc25A requires ATR, Claspin and Chk1 signaling (13,14). C-terminal phosphorylation of Cdc25A by Chk1 (together with N-terminal phosphorylation by an unknown kinase) targets Cdc25A to an SCF complex containing β-TrCP (15-17). It is thought that the DSB-induced intra-S-phase checkpoint targets Cdc25A through Chk2-mediated amplification of Chk1-dependent systems (13,18). Thus, loss of Chk1 results in accumulation of hypo-phosphorylated Cdc25A and failure to degrade Cdc25A after IR (19). The decrease in Cdk2 activity resulting from IR-induced Cdc25A degradation is likely to contribute to the S-phase checkpoint. Consistent with a Cdc25A/Cdk2-mediated mechanism for the S-phase checkpoint, association of the Cdc45 replication factor with origins of replication (a late Cdk2-dependent event in initiation of DNA replication), is inhibited in response to IR concomitant with Cdc25A degradation (20).

Although previous studies have demonstrated that Cdc25A is degraded in response to IR-induced DSBs (19), it is not clear whether Cdc25A is degraded in response to other forms of DNA damage such as bulky adducts or if Cdc25A represents a universal target of S-phase checkpoint signaling pathways. Moreover, as noted above, BPDE and other genotoxins elicit dose-dependent inhibition of initiation (i.e. the S-phase checkpoint) and inhibition of elongation (i.e. replication blocks), yet it is unclear if Chk1-
mediated Cdc25A degradation is involved in one or both responses.

Another possible target of the S-phase checkpoint is the essential protein kinase Cdc7 (21). Cdc7 and its activating subunits (Dbf4 and Drf1) are required for DNA synthesis and appear to regulate initiation of replication at individual origins during S-phase (22). The precise mechanism by which Cdc7 promotes initiation is not known. However, the Mcm2-7 complex is a substrate of Cdc7 in vitro and in intact cells (23,24) and is likely to be involved in Cdc7-mediated initiation of DNA synthesis. Several studies have suggested that Cdc7 is a target of S-phase checkpoint signaling. For example, the S. pombe and S. cerevisiae Dbf4 orthologs (Dfp1 and Dbf4 respectively) interact with checkpoint kinases, and yeast mutants in Dbf4 and Cdc7 are sensitive to genotoxic agents (25,26). Gautier and colleagues showed that Dbf4, the activating partner of the Cdc7 kinase, is targeted by DNA damage signaling in replication-competent Xenopus egg extracts (27). In those experiments, etoposide (a Topoisomerase II inhibitor) inhibited the association of Dbf4 with chromatin-bound Cdc7, concomitant with inhibition of DNA synthesis. Furthermore, addition of exogenous Dbf4 allowed replication of etoposide-treated nuclei, demonstrating that Dbf4 was rate-limiting for DNA synthesis after etoposide-treatment. Using Xenopus extracts, Dunphy and colleagues have shown that Drf1 associates with chromatin in response to DNA damage and replication stress (28). Therefore, these workers have suggested that Drf1 might be involved in S-phase checkpoint responses, and that its association with chromatin could provide a mechanism for S-phase inhibition. However, it is not yet clear whether Dbf4/Cdc7 is targeted by S-phase checkpoint signaling in response to all genotoxins or if Cdc7 is involved in inhibition of initiation, replication blocks, or both responses. Some recent studies have suggested that Dbf4 is dispensable for DNA synthesis in Xenopus egg extracts (29), possibly indicating a requirement for alternative Dbf4-independent mechanisms for S-phase checkpoint control.

Therefore, in experiments described here, we have investigated possible roles of Cdc25A, Cdk2, and Cdc7/Dbf4 in the BPDE-induced S-phase checkpoint. We show that Cdc25A/Cdk2 and Cdc7/Dbf4 are affected by high doses of BPDE that inhibit elongation, but not by low doses of BPDE that induce Chk1-dependent inhibition of DNA synthesis. Consistent with these results, we show that Cdc25A/Cdk2 and Dbf4/Cdc7 are not rate-limiting for DNA synthesis in cells treated with low doses of BPDE. To identify relevant targets of the S-phase checkpoint we have tested the effects of low dose BPDE treatment on the replication factors. Our results indicate that the association between the initiation factor Cdc45 and Mcm7 is targeted by the BPDE-induced S-phase checkpoint.

Materials and Methods

Cell Culture.
H1299, A549 and Hela cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and streptomycin sulfate (100 µg/ml) and penicillin (100 units/ml). The CHO-derived cell line A03_1 was maintained in MEM containing 10% fetal bovine serum and 0.3 µM methotrexate (Calbiochem).

Adenovirus Construction and Infection.
Adenovirus construction and infections were performed as described previously (4,30). In brief, cDNAs encoding Cyclin A, Cdk2, and p21 were subcloned into pAC-CMV to generate shuttle vectors. The resulting constructs were co-transfected into 293T cells with the pJM17 plasmid to generate recombinant adenovirus as described previously (4). H1299 cells were routinely infected with at 5x10⁹ pfu/ml of adenovirus. As controls for adenoviral infection, cells received AdCon (‘empty’ adenovirus vector) or AdGFP.

Genotoxic Treatments.
BPDE (NCI carcinogen repository) was dissolved in anhydrous Me₂SO and added directly to the growth medium as a 1000 x stock to give final concentrations as indicated. In some experiments, cells were incubated in medium containing 5 mM caffeine (Sigma) or 150 nM UCN-01 for 1 hr before genotoxic treatment. UVC treatments were performed using a UV crosslinker (Stratagene) as described previously (31). The UVC dose
delivered to the cells was confirmed with a UV radiometer (UVP, Inc.).

**RNA interference.**
The non-targeting control siRNA (Cat# D-001210-01) and human Chk1 siRNA (siCHEK1, Smartpool, Cat# M-003255-02) oligonucleotides were obtained from Dharmacon (Lafayette, CO). siRNA transfection experiments were carried out using Lipofectamine 2000 (Invitrogen) according the manufacturer's instructions. H1299 cells were transfected with 100 nM (final concentration) non-targeting control siRNA or Chk1 siRNA. 48 hours following transfection, the cells were treated with genotoxin BPDE for 2 hours, the resulting cultures were used to analyze the expression level of Cdc45 and Chk1.

**DNA Synthesis Assays.**
Cells were plated in 12-well culture dishes and grown to 60% confluence. Genotoxin treatments were performed as described above. To measure DNA synthesis at different time points after genotoxin treatment replicate wells received [3H]-thymidine (1 µCi/ml, PerkinElmer Life Sciences) for 30 min. At the end of the labeling period, the [3H]-thymidine-containing medium was aspirated, and the monolayers were fixed by addition of 5% trichloroacetic acid. The fixed cells were washed three times with 5% trichloroacetic acid to remove unincorporated [3H]-thymidine. The trichloroacetic acid-fixed cells were solubilized in 0.3 M NaOH. A 300 µl aliquot of the NaOH-solubilized material was transferred to a scintillation vial and neutralized by addition of 100 µl of glacial acetic acid. After addition of 5 ml of Ecoscint scintillation fluid, incorporated [3H]-thymidine was measured by scintillation counting.

**Velocity Sedimentation Analysis**
Velocity sedimentation analysis was performed as previously described by Cordeiro-Stone et al. (32) with slight modifications. Briefly, H1299 cells were plated at 5x10⁵ cells per 60 mm plate with 2 plates per condition. Following a 30 hour incubation with 10 nCi/mL [14C]-thymidine, the radiolabeled medium was replaced with unlabeled medium for 24 hours. Cells were treated either with BPDE at the indicated concentrations or DMSO for 1 hour before pulsing with [3H]-thymidine at 10 µCi/mL for 15 minutes. Cells were scraped into a solution of 0.1 M NaCl with 0.01 M EDTA (pH 8.0). A volume of 500 µL of lysis buffer (0.5 M NaOH, 0.1 M EDTA (pH 8.0)) was layered on top of a linear sucrose gradient (5-20%) and 500 µL of cell suspension was added to this layer. Gradients were kept at 4 °C for 15 hours under fluorescent lights and subsequently centrifuged for 4 hours at 25K RPM at 20 °C. Approximately 28 equal fractions were collected and acid-precipitated on glass microfiber filters. Radioactivity was determined by scintillation counting.

**Immunoblotting.**
Total cell lysates were prepared in lysis buffer containing 50 mM Heps, pH 7.4, 0.1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 50 mM NaF, 80 mM β-glycerophosphate, and 1 x protease inhibitor mixture (Roche Applied Science). In some experiments, cells were fractionated to generate soluble fractions and whole nuclei, exactly as described previously by Izumi et al. (33). In brief, monolayers of cells were washed three times in ice-cold phosphate-buffered saline (PBS) and scraped into 500 µl of ice-cold cytoskeleton buffer (CSK buffer: 10 mM PIPES, pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl₂, 1mM EGTA, 1mM DTT, 0.1 mM ATP, 1 mM Na₃VO₄, 10 mM NaF and 0.1% Triton X-100) freshly supplemented with 0.2 mM phenylmethylsulphonyl fluoride and protease inhibitor cocktail. CSK lysates were transferred to microcentrifuge tubes and incubated on ice for 5 minutes. The cell lysates were centrifuged at 1,000 g for 2 minutes. The supernatants were removed and further clarified by centrifugation at 10,000 g for 10 minutes to obtain Triton X-100-soluble fractions. The Triton-extracted insoluble nuclear fractions were washed once with 1 ml of CSK buffer and then re-suspended in a minimal volume of CSK. In some experiments, chromatin-bound proteins were released by digestion of nuclei in CSK with 1000 U/ml of RNase-free DNase I (Roche) at 25°C for 30 minutes. After digestion, soluble and insoluble materials were separated by centrifugation at 10,000g for 10 minutes. Total cell extracts or nuclear protein samples were separated by SDS-PAGE, transferred to nitrocellulose, and analyzed by immunoblotting with the following antibodies: Cdc7 (MBL), Cdc25A, PCNA, Mem7 (Santa Cruz
Biotechnology), Mcm10 (Bethyl Laboratories Inc.), and Cdc45 (34).

Immunoprecipitations and Cdk2 Assays.
These experiments were performed exactly as described by Rosenblatt et al. (35). In brief, Cdk2 was immunoprecipitated from cell lysates and the washed immune complexes were incubated with histone H1 and \[^{32}P\]ATP. Phosphorylated histone was electrophoresed on SDS-polyacrylamide gels and visualized by autoradiography. To quantify Cdk2 activity, histone bands were excised from dried gels and the amount of incorporated \[^{32}P\] was measured by Cerenkov counting.

Chromatin decondensation assay.
Chromatin decondensation analyses were performed exactly as described by Alexandrow and Hamlin (36) using A03_1 cells. A03_1 cells contain a 90 Mb homogenously staining region (HSR) consisting of 60 amplicons each containing ~400 kb of tandemly-arrayed 14 kb lac operator (lacO) / dihydrofolate reductase (DHFR) vector (37). The HSR can be visualized by providing the LacI protein. When visualized microscopically by an anti-Lac antibody, the HSR assumes a dot-like structure and is heterochromatic. The recruitment of Cdc45 to the HSR (using a LacI-Cdc45 fusion protein) induces a dramatic decondensation of the HSR (36). To determine the effect of checkpoint signaling on Cdc45-induced chromatin decondensation, A03_1 cells were plated on glass slides, grown to 50% confluence, and then transfected with pRcLacI or pRcLacI-Cdc45 (5 µg/slide) for 24 hours using Lipofectamine 2000 (Invitrogen). In some experiments, CMV-Chk1 (or empty vector for control) was co-transfected at a ratio 3:1 with Lacl-Cdc45. After 20 hours of transfection, cells were treated with or without BPDE, Caffeine and UCN-01 as indicated in the figure legends. Genotoxin-treated cells were incubated with 1% formaldehyde for 10 minutes to generate cross-linked protein-DNA complexes. The crosslinking reaction was quenched by adding glycine to a final concentration of 125 mM for 10 minutes. The glycine-containing medium was aspirated and the cells were washed twice using ice cold PBS containing protease inhibitors and 1 mM PMSF. The cells were scraped into a conical tube and collected by brief centrifugation. The resulting cells were re-suspended in 0.35 ml of lysis buffer (50 mM Tris-HCl, pH 8.0, 1% paraformaldehyde for 10 min. After permeabilizing with 0.2% Triton X-100 for 5 min, the slides were blocked with 10% fetal bovine serum and 1% BSA in PBS for 1 hour and then incubated with monoclonal anti-LacI antibody (Upstate, Clone 9A5) at 1:2,000 dilution for 1 hour at room temperature. Slides were then washed in 0.1% PBST and incubated with FITC-conjugated goat anti-mouse IgG (Jackson ImmunoResearch) for 1 hr. After extensive washing to remove unbound antibody, the slides were mounted with DAPI-containing Vectashield medium (Vector Laboratories, Inc.). Slides were visualized using fluorescence microscopy. To determine relative numbers of cells containing condensed and decondensed chromatin structures, 200 cells were scored visually for each experimental condition, according to the classification used by Alexandrow and Hamlin (36). The HSR was considered to be condensed if the fluorescent image occupied 2-5% of the nuclear area, decondensed if it occupied > 10% of the nuclear area, and indeterminate if it occupied 5-10% of the nuclear area. Representative cells showing condensed and de-condensed HSR were photographed using a Delta Vision Image Restoration Microscopy System (Applied Precision).

Chromatin Immunoprecipitation (ChIP) assays.
A 150 cm² dish H1299 cells was used for each ChIP. Sub-confluent H1299 cells were treated with or without BPDE, Caffeine and UCN-01 as indicated in the figure legends. Genotoxin-treated cells were incubated with 1% formaldehyde for 10 minutes to generate cross-linked protein-DNA complexes. The crosslinking reaction was quenched by adding glycine to a final concentration of 125 mM for 10 minutes. The glycine-containing medium was aspirated and the cells were washed twice using ice cold PBS containing protease inhibitors and 1 mM PMSF. The cells were scraped into a conical tube and collected by brief centrifugation. The resulting cells were re-suspended in 1 ml of collection buffer (0.1 M Tris-HCl (pH 9.4), 0.1 M DTT), placed on ice for 5 minutes, and incubated at 30°C for 15 minutes. Then, cells were collected by centrifugation, and washed sequentially in 1 ml ice cold PBS, 1 ml of 10 mM Hepes pH (6.5), 0.25% Triton X-100, 10 mM EDTA, 0.5 mM EGTA and finally in 1 ml of 10 mM Hepes (pH 6.5), 1 mM EDTA, 0.5 mM EGTA, 200 mM NaCl. The resulting cells were resuspended in 0.35 ml of lysis buffer (50 mM Tris-HCl, pH 8.0, 1% SDS, 10 mM EDTA) supplemented with 1x protease inhibitor cocktail, then incubated on ice for 15 minutes. The resulting lysates were sonicated on ice to shear the DNA into 200-1000 bp fragments. Sonicated lysates were centrifuged for 10 min at 10,000g. The clarified supernatants containing chromatin fragments were transferred...
to new tubes and normalized for protein content. 5% of each sheared chromatin sample was saved to provide an 'input' control. The remainder of each chromatin solution was diluted to 1 ml using IP buffer (20 mM Tris-Cl, pH 8.0, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl) freshly supplemented with a protease inhibitor cocktail. Each sample was then pre-cleared with 40 µl of a 50% protein A-agarose slurry for 4 hrs at 4°C. Pre-cleared samples were immunoprecipitated with 2-5 µg rabbit anti-H4 (Upstate) as a positive control for the IPs, rabbit pre-immune serum as a negative control, or rat anti-Cdc45 monoclonal antibody (38). After incubation at 4°C overnight, 40 µl of pre-blocked protein G-agarose beads was added to each sample. 3 hrs later, immune complexes were collected by centrifugation. Beads were washed sequentially with 1 ml Wash Buffer 1 (20 mM Tris-Cl, pH 8.0, 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl), 1 ml Wash Buffer 2 (20 mM Tris-Cl (pH 8.0), 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl), 1ml of Wash Buffer 3 (10 mM Tris-Cl (pH 8.0), 0.25 M LiCl, 1% NP-40, 1% Deoxycholate; 1 mM EDTA), and finally with 1 ml TE buffer. Chromatin was eluted from the beads using 250 µl of 1% SDS in 0.1 M NaHCO₃. Reverse crosslinking was performed by overnight incubation at 45°C in the presence of 10 µg/ml of proteinase K and RNAse A. After phenol/chloroform extraction and ethanol precipitation, immunoprecipitated DNA was resuspended in 50 µl of distilled water and analyzed by PCR. We synthesized PCR primers designed to amplify a 400 bp region of the β-globin replicator (39,40). Previous workers have used identical primers to measure association of Rb with the β-globin origin in ChIP assays (41). Sequences of the PCR primers we used to amplify the β-globin locus are: forward 5' -GAGTGAAACAGGCAACCTACAAATGGG-3'; reverse 5'-TCTCCATCTCCTAGGCGACCTTG-3'. The amplified DNA products were separated on 1% agarose gels and visualized under an UV transilluminator.

Reproducibility.

All data shown are representative of experiments that were repeated at least three times with similar results on each separate occasion.

Results

Cdc25A and Cdk2 are not targets of the BPDE-induced S-phase checkpoint. Chk1 mediates the S-phase checkpoint induced by low doses (<100 nM) of BPDE (4,9). The downstream target(s) of Chk1 that mediate the S-phase checkpoint induced by bulky adducts (such as BPDE or UV-induced thymine dimers) are not known. However, several reports have implicated Cdc25A as a target of Chk1 in the IR-induced S-phase checkpoint (13,15,16,42). Therefore, we asked if Cdc25A was a relevant target of Chk1 in the bulky adduct-induced S-phase checkpoint resulting from BPDE-treatment. We have studied regulation of DNA replication extensively in H1299 lung carcinoma cells and have shown that the BPDE-induced S-phase checkpoint is intact in this cell line (4,30,31,43). Therefore, we chose H1299 cells for these experiments.

First, we determined whether the IR-induced Cdc25A degradation pathway is functional in H1299 cells. Exponentially-growing H1299 cells were treated with IR (10 Gy) as described under 'Materials and Methods'. We measured rates of DNA synthesis and Cdc25A levels in the cells at various times after irradiation. As shown in Fig. 1A, rates of DNA synthesis (as measured by [3H]-thymidine incorporation) were reduced by ~30% 120 minutes after irradiation. Consistent with previous reports from other investigators, Cdc25A levels and levels of chromatin-associated Cdc45 were decreased concomitantly with inhibition of DNA synthesis (20,44) following IR treatment (Fig. 1B). Therefore, we concluded that the IR-induced checkpoint pathway leading to Cdc25A degradation is intact in H1299 cells.

Next, we determined the effects of different doses of BPDE on DNA synthesis and Cdc25A levels. 50 nM BPDE inhibited DNA synthesis (measured by [3H]-thymidine incorporation assays) by ~70% for 2-4 hrs (Fig. 2A). However, the cells recovered from inhibition of DNA synthesis approximately 8 hrs after BPDE-treatment (Fig. 2A). Velocity sedimentation analysis showed that

Reproducibility.
50 nM BPDE elicited a selective loss of newly-initiated low molecular weight DNA (fractions 18-26 in the sedimentation profiles of Fig. 2A). In contrast, 600 nM BPDE elicited a sustained inhibition of DNA synthesis as measured by [3H]-thymidine incorporation (Fig. 2A). Velocity sedimentation analyses demonstrated that inhibition of DNA synthesis in response to 600 nM BPDE was due to loss of high molecular weight DNA (fractions 10-21 in Fig 2A), and therefore represents reduced elongation (i.e. replication blocks).

Interestingly, Cdc25A levels were similar to control levels at time points when DNA synthesis was inhibited by treatment with 100 nM BPDE (Fig. 2B). However, Cdc25A expression was reduced to 42% of control levels 1 hr after treatment with 600 nM BPDE. Therefore, the BPDE-induced S-phase checkpoint occurs without significant changes in Cdc25A levels. In contrast, high doses of BPDE that inhibit elongation reduce Cdc25A levels.

Checkpoint signaling pathways often inhibit the Cdk5 that drive cell cycle progression. Since Cdc25A levels were unchanged in response to 100 nM BPDE, we considered the possibility that the BPDE-induced S-phase checkpoint signaling pathway might target Cdk2 activity via Cdc25A-independent mechanism(s). Therefore, we measured the histone kinase activity of immunoprecipitated Cdk2 from control and BPDE-treated cells. As shown in Fig. 2C, 100 nM BPDE had no effect on Cdk2 activity whereas 600 nM BPDE inhibited Cdk2 by 60%. As positive and negative controls for these Cdk2 assays we performed similar assays using anti-Cdk2 immunoprecipitates from cells over-expressing Cyclin A + Cdk2 or from cells over-expressing p21. As shown in Fig. 2C, the 600 nM BPDE-induced inhibition of Cdk2 activity was largely prevented in Cyclin A + Cdk2-overexpressing cells. Also as expected, over-expression of the Cdk inhibitor p21 inhibited Cdk2 activity by 95% (Fig. 2C).

The results of our Cdk2 assays were consistent with our immunoblotting experiments showing that Cdc25A levels are unaffected when the BPDE-induced S-phase checkpoint is active (after treatment with <100 nM BPDE), but that Cdc25A levels decrease in response to global replication blocks (resulting from treatment with 600 nM BPDE). Taken together, our results show that BPDE concentrations that activate the S-phase checkpoint do not affect Cdc25A levels or Cdk2 activity, and that Cdc25A/Cdk2 signaling is unlikely to be a target of the S-phase checkpoint. In contrast, BPDE concentrations that induce global replication blocks inhibit both Cdc25A expression and Cdk2 activity.

It was possible that low doses of BPDE induced small changes in Cdc25A expression (or Cdk2 activity) that were undetectable in our standard assays. Potentially, even small decreases in Cdc25A expression or Cdk2 activity that are below the sensitivity level of our assays could contribute to inhibition of DNA synthesis. Therefore, to test if Cdc25A levels or Cdk2 activity are rate-limiting for DNA synthesis after treatment with 100 nM BPDE we determined the effect of ectopically-expressed Cdc25A and Cyclin A + Cdk2 on the S-phase checkpoint. H1299 cells were infected with adenovirus encoding Cdc25A (AdCdc25A), Cdk2 + Cyclin A (AdCdk2 + AdCyclin A), or with an 'empty' control adenovirus vector (AdCon). As shown in Fig. 2D, BPDE treatment inhibited DNA synthesis to a similar extent (approximately 40%) in control, Cdc25A-over-expressing, or Cyclin A + Cdk2 over-expressing cells. Therefore, Cdc25A levels and Cyclin A-Cdk2 activity are not rate-limiting for DNA synthesis when the BPDE-induced S-phase checkpoint is active.

Role of Cdc7 in BPDE-induced S-phase checkpoint signaling. Gautier and colleagues showed that Dbf4, the activating partner of the Cdc7 kinase, is targeted by DNA damage signaling in replication-competent Xenopus egg extracts (27). In those experiments, etoposide (a Topoisomerase II inhibitor) inhibited the association of Dbf4 with chromatin-bound Cdc7, concomitant with inhibition of DNA synthesis. Furthermore, addition of exogenous Ddf4 allowed replication of etoposide-treated nuclei, demonstrating that Dbf4 was rate-limiting for DNA synthesis after etoposide-treatment.
Therefore, we tested a possible role for Cdc7 in the BPDE-induced S-phase checkpoint. We determined the effect of BPDE on the association between Cdc7 and Dbf4. H1299 cells were transiently transfected with CMV-FLAG-Dbf4 and CMV-Cdc7 expression vectors. As expected, Cdc7 was present in anti-FLAG immunoprecipitates from FLAG-Dbf4-expressing (but not from GFP-transfected) cells (Fig. 3). We determined the effect of BPDE on the association between FLAG-Dbf4 and Cdc7. As shown in Fig. 3, FLAG-Dbf4-associated Cdc7 was readily detected in extracts from cells that did not receive BPDE. Treatment with 100 nM BPDE had no effect on the association between Dbf4 and Cdc7, demonstrating that Cdc7-Dbf4 interactions are not affected when checkpoint signaling inhibits initiation of replication. However, high doses of BPDE that inhibit elongation also reduced the association between Dbf4 and Cdc7 (Fig. 3).

Gautier and colleagues showed that ectopically added Dbf4 could bypass the etoposide-induced inhibition of DNA synthesis in Xenopus extracts (27). We performed similar experiments to determine whether Dbf4-levels were rate-limiting for initiation of DNA replication after 100 nM BPDE treatment (when the S-phase checkpoint is activated). H1299 cells were transfected with a GFP expression vector for control (and to assess transfection efficiency), or with CMV-FLAG-Dbf4. Immunofluorescence microscopy of GFP-transfected cells indicated a transfection efficiency of ~90% in these experiments. Similar to the results of Fig. 3, immunoblot analyses demonstrated that FLAG-Dbf4 was expressed efficiently in transfected cells (data not shown). The resulting cultures were treated with BPDE for 2 hrs. In a representative experiment, BPDE inhibited DNA synthesis both in GFP-transfected, and in Dbf4-over-expressing cells (42% and 39% inhibition respectively). In other experiments, co-expression of Cdc7 with Dbf4 similarly failed to abrogate the S-phase checkpoint (data not shown). Therefore, high level expression of Dbf4 (or Dbf4 + Cdc7) did not affect the S-phase checkpoint and in contrast to etoposide-treated Xenopus nuclei, Dbf4 is unlikely to be rate-limiting for DNA synthesis in BPDE-treated H1299 cells.

Effect of BPDE on chromatin-association of DNA replication factors. Our analyses indicated that Cdc25A, Cdk2, and Cdc7 were unlikely to be targets of the S-phase checkpoint. To investigate alternative possible targets for the BPDE-induced checkpoint we tested the effects of BPDE on DNA replication factors. During S-phase, the actions of Cdk2 and Cdc7 promote the ordered recruitment of initiation factors, such as Mcm10 and Cdc45 to origins of replication (45). Cdc45 loading is one of the latest events in initiation of replication and is crucial for unwinding of origin DNA and binding of replicative DNA polymerases (a step also termed 'origin firing'). In addition, recent studies have demonstrated that Cdc45 is also important for elongation (38). Chromatin-association of Mcm10 and Cdc45 correlates well with initiation of DNA synthesis. For example, stimulation of origin firing by ectopic over-expression of Cdt1 in H1299 cells resulted in large increases in chromatin-associated Mcm10 and Cdc45 (Fig. 4A).

Since the BPDE-induced checkpoint inhibits initiation of replication, we sought to determine whether the chromatin-association of initiation factors is sensitive to BPDE. Therefore, H1299 cells were treated with 60 nM or 600 nM BPDE. At different times after BPDE treatment, we determined levels of various replication factors including Mcm7 (a pre-Replication Complex or pre-RC component), Mcm10 and Cdc45 and PCNA (a DNA polymerase processivity factor) in soluble and chromatin fractions. As shown in Fig. 4B, levels of chromatin-associated Mcm7, PCNA, and Mcm10 were unchanged at all times after treatment with 60 nM or 600 nM BPDE. However, 60 nM BPDE transiently decreased the amount of chromatin-associated Cdc45 by ~60% (Fig. 4B). The loss of chromatin-bound Cdc45 after treatment with 60 nM BPDE was coincident with Chk1 phosphorylation on Ser 317 and inhibition of DNA synthesis (see Fig. 2A). Increased Chk2 phosphorylation (on Thr68) was not detected in response to 60 nM BPDE when initiation of DNA replication was inhibited, consistent with our previous finding that the BPDE-induced S-phase checkpoint is Chk2-independent (4). Eight hours after 60 nM BPDE treatment, when rates of DNA
synthesis had returned to control levels (Fig. 2A), the chromatin-association of Cdc45 was also restored (Fig. 4B).

When we treated cells with 600 nM BPDE (a dose that inhibits initiation and elongation), chromatin-associated Cdc45 levels were also reduced (Fig. 4B). Both Chk1 and Chk2 were phosphorylated persistently in response to 600 nM BPDE (indicating activation of ATR/Chk1 and ATM Chk2 pathways in response to global elongation blocks). Similar to checkpoint kinase activation and inhibition of DNA synthesis, the loss of chromatin-bound Cdc45 induced by 600 nM BPDE was irreversible (Fig. 4B). Levels of soluble Cdc45 were unaffected by BPDE, indicating that DNA damage specifically affects the chromatin-bound fraction of Cdc45 that is actively engaged in DNA replication. The levels of chromatin-bound Mcm10, Mcm7, and PCNA were unaffected by BPDE treatment (Fig. 4B). Therefore, BPDE concentrations as high as 600 nM do not cause a global dissociation of replication factors from chromatin.

We previously showed that Chk1 mediates BPDE-induced PCNA mono-ubiquitination, thereby recruiting the Trans-Lesion Synthesis (TLS) DNA polymerase Polκ to replication forks at sites of DNA damage (43). Polκ-mediated lesion bypass attenuates Chk1 signaling, and permits resumption of DNA synthesis following checkpoint-mediated S-phase arrest (31). As shown in Fig. 4B, loss of chromatin-associated Cdc45 in BPDE-treated cells coincided with Chk1 activation and PCNA ubiquitination. Moreover, the transient PCNA mono-ubiquitination induced by 60 nM BPDE preceded the re-association of Cdc45 with chromatin at 8 hrs. Therefore, loss of Cdc45 from chromatin after treatment with 60 nM BPDE correlates temporally with S-phase checkpoint activation. Furthermore, re-association of Cdc45 with chromatin occurs subsequent to TLS and correlates well with the recovery phase of the S-phase checkpoint.

To test whether the BPDE-induced decrease in chromatin-bound Cdc45 was Chk1-mediated we ablated Chk1 expression using siRNA. As shown in Fig. 4C, The BPDE-induced loss of chromatin-associated Cdc45 was largely attenuated in Chk1-depleted cells (Fig. 4C). Therefore, the BPDE-induced decrease in chromatin-associated Cdc45 requires Chk1.

Taken together, these data show that the association of Cdc45 with chromatin is sensitive to low doses of BPDE that reversibly inhibit initiation as well as high doses of BPDE that irreversibly inhibit initiation and elongation. These findings are consistent with regulation of Cdc45-chromatin association by the BPDE-induced S-phase checkpoint. As noted previously, the recruitment of Cdc45 to pre-RCs requires prior Mcm10 loading (46). Since BPDE affected chromatin-association of Cdc45 but not of Mcm10, our data indicate that BPDE-induced checkpoint signaling affects initiation at a stage subsequent to Mcm10 recruitment but prior to Cdc45 loading.

Effect of BPDE on association between Mcm7 and Cdc45. Cdc45 interacts directly with Mcm7 in vitro and has been proposed to help tethering Polα to the replication complex during initiation (47). Since BPDE treatment inhibited the chromatin association of Cdc45, it was of interest to determine if the interaction between Cdc45 and Mcm7 was disrupted concomitant with activation of the S-phase checkpoint.

As expected, Cdc45 was immunoprecipitated with anti-Mcm7, but not with a control non-specific IgG (Fig. 5A). We performed immunoprecipitations and immunoblot analyses to determine the levels of Mcm7-associated Cdc45 in soluble and chromatin fractions at different times after BPDE treatment. As expected from the results of Fig. 4, BPDE did not affect levels of soluble or chromatin-bound Mcm7 (Fig. 5B). However, 2 hrs and 4 hrs after treatment with 60 nM BPDE, levels of Mcm7-associated Cdc45 in chromatin fractions were decreased (by 59% and 70% respectively) concomitant with inhibition of DNA synthesis (Fig. 5B). At 8 hrs after treatment with 60 nM BPDE the association between Cdc45 and Mcm7 in the chromatin fraction was restored to 91% of control levels concomitant with resumption of DNA synthesis (Fig. 5B). The persistent inhibition of DNA synthesis elicited by 600 nM BPDE also induced an irreversible decrease in the interaction between chromatin-
associated Mcm7 and Cdc45. BPDE did not affect the association between Mcm7 and Cdc45 in the soluble fraction (Fig. 5C). We considered the possibility that the effect of BPDE on Mcm7-association of Cdc45 was a general effect of DNA damaging agents on interactions between Mcm7 and its binding partners. Mcm7 associates with the Rb tumor suppressor protein, and this interaction has been proposed to negatively regulate DNA synthesis. We tested the effect of BPDE on the association between Mcm7 and Rb. As shown in Figs. 5B and 5C, the association between soluble or chromatin-bound Mcm7 and Rb was unaffected by BPDE. Therefore, the inhibitory effect of BPDE on the association between Mcm7 and Cdc45 is relatively specific.

We have previously shown that the Chk1 inhibitor UCN-01 inhibits the BPDE-induced S-phase checkpoint in H1299 cells (4). To test whether the effect of BPDE on association between Cdc45 and Mcm7 is Chk1-mediated, we determined the effect of UCN-01 on BPDE-induced dissociation of Cdc45-Mcm7 interactions. As shown in Fig. 5D, 4 hrs after treatment with 60 nM BPDE, the levels of Mcm7-associated Cdc45 were decreased transiently (to 29% of control), then restored 8 hr after BPDE treatment when DNA synthesis resumed. In contrast, in UCN-01-treated cells, the levels of Mcm7-associated Cdc45 were unaffected by 60 BPDE (Fig. 5D). Therefore, UCN-01 prevents the S-phase checkpoint-mediated dissociation of Cdc45 from Mcm7.

In a parallel experiment, we determined the effect of UCN-01 on Mcm7-Cdc45 associations in cells treated with 600 nM BPDE. In contrast with the S-phase arrest-induced by 60 nM BPDE, 600 nM BPDE-induced S-phase arrest is due mainly to elongation blocks and is insensitive to Chk1 inhibition (4). As shown in Fig. 5D, UCN-01 did not prevent the dissociation of Cdc45 from Mcm7 after 600 nM BPDE-induced replication blocks.

Taken together, our data suggest that Chk1 signaling inhibits DNA synthesis by targeting the interaction between Cdc45 and Mcm7 when the BPDE-induced S-phase checkpoint is active. However, replication blocks inhibit the Cdc45-Mcm7 interaction in a Chk1 independent manner.

BPDE and checkpoint signaling regulate association between Cdc45 and a defined replicator. The S-phase checkpoint is thought to downregulate the activities of replication origins during S-phase (3). If as suggested by our immunoblotting analyses Cdc45 is a target of the BPDE-induced checkpoint, we predicted that the association of Cdc45 with unfired origins of DNA replication would be sensitive to DNA damage signaling. Therefore, we performed chromatin immunoprecipitations (ChIP) to examine the effect of BPDE on the association between Cdc45 and a known origin of replication, namely the β-globin locus (39).

As shown in Fig. 6A, our Cdc45 antibody (but not a control non-specific antibody) efficiently immunoprecipitated the β-globin origin of replication from chromatin fractions of untreated H1299 cells (lane 6). However, anti-Cdc45 immunoprecipitates of chromatin derived from BPDE-treated cells (100 nM or 600 nM BPDE) did not contain detectable levels of β-globin genomic DNA (lanes 7 and 8). Therefore, BPDE-treatment prevents association of Cdc45 with the β-globin origin of replication.

If the effect of BPDE on association between Cdc45 and the β-globin origin resulted from checkpoint signaling, we predicted that inhibition of checkpoint signaling would permit association between Cdc45 and the β-globin locus in BPDE-treated cells. We previously showed that caffeine (an ATR inhibitor) and UCN-01 (a Chk1 inhibitor) prevent the inhibition of DNA synthesis induced by BPDE (4). Therefore, we tested the effects of caffeine and UCN-01 on BPDE-induced dissociation of Cdc45 from the β-globin locus. As expected, BPDE treatment inhibited the association between Cdc45 and the β-globin origin (Fig. 6B). Treatment with caffeine or UCN-01 alone increased the basal level of association between Cdc45 and the β-globin locus. This result is consistent with recent suggestions that the ATR/Chk1 pathway suppresses late origin firing and maintains ordered regulation of DNA synthesis in the absence of genotoxic insult (50). Importantly, caffeine and UCN-01 treatments also allowed association between Cdc45 and the β-globin origin in BPDE-treated cells (Fig. 6B).
Therefore, inhibition of the ATR/Chk1 signaling pathway permits Cdc45 association at a defined origin of replication. Taken together, the results of our ChIP analyses are consistent with a role for Cdc45 as a target of the BPDE-induced S-phase checkpoint pathway.

**Effect of BPDE on Cdc45-induced chromatin decondensation.** Although Cdc45 is essential for initiation of DNA replication, its precise biochemical activity and role in DNA replication remain unclear. Recently, it was shown that targeting Cdc45 to specific chromosomal sites in A03_1 hamster cells results in large-scale chromatin decondensation (36). Alexandrow and Hamlin targeted LacI-Cdc45 (or LacI for control) to a ~400 kb homogenously-staining region (HSR) containing multiple copies of an integrated lac operator/DHFR vector. In those experiments, the HSR was visualized by immunofluorescence microscopy with anti-LacI. Ordinarily, the LacI-bound HSR assumed a condensed dot-like structure. However, targeting a Ccd45-LacI fusion protein to the HSR resulted in dramatic chromatin decondensation (36).

Cdc45-induced chromatin decondensation might facilitate initiation of DNA synthesis and fork progression during replication (36). We hypothesized that if Cdc45 represents a relevant target of the BPDE-induced S-phase checkpoint, its chromatin-decondensing activity might be negatively regulated by DNA damage signaling. Therefore, we tested the effects of BPDE and Chk1 on Cdc45-induced chromatin decondensation using the experimental strategy devised by Alexandrow and Hamlin (36).

First we verified that the BPDE-induced S-phase checkpoint was intact and Cdc25A-independent in A03_1 cells. We treated exponentially-growing A03_1 cells with 60 nM BPDE for 2 hours, then measured rates of DNA synthesis and Cdc25A levels. As shown in Fig. 7A, rates of DNA synthesis were reduced by BPDE treatment, and the BPDE-induced inhibition of [3H]-thymidine incorporation was prevented by pre-treatment with UCN-01. We were unable to determine the effect of BPDE on endogenous Cdc45 in A03_1 cells because our antibody does not recognize hamster Cdc45. However, immunoblotting experiments showed that BPDE-induced inhibition of DNA synthesis occurred in the absence of changes in Cdc25A levels (Fig. 7B). Taken together, these results demonstrate that the BPDE-induced S-phase checkpoint is functional and independent of changes in Cdc25A expression in A03_1 cells.

Having confirmed that the BPDE-induced S-phase checkpoint was intact in A03_1 cells, we determined the effect of BPDE on Cdc45-induced chromatin decondensation. Fig. 7C shows examples of the typical condensed dot-like HSR structures seen in LacI-transfected cells (upper panels) as well as the de-condensed HSRs elicited by LacI-Cdc45 (second panels from top). As shown in Figs. 7C (third panel from top) and 7D, treatment with 100 nM BPDE reduced the number of cells containing decondensed chromatin by >50%, indicating that BPDE inhibited Cdc45-induced chromatin-decondensation. Interestingly, co-transfection of LacI-Cdc45 with a Chk1 expression vector also inhibited Cdc45-induced chromatin decondensation, even in the absence of BPDE (bottom panels). We have previously shown that over-expressed Chk1 induces a DNA damage-independent S-phase arrest (4). Taken together, our data demonstrate that BPDE or over-expressed Chk1 inhibit Cdc45-induced chromatin decondensation. These results are consistent with a role for Cdc45 as a target of the BPDE-induced S-phase checkpoint.

The UVC-induced S-phase checkpoint targets Cdc45 independently of Cdc25A. It was of interest to determine whether the Cdc25A-independent effect of BPDE on Cdc45 is a general response to genotoxins. Similar to BPDE-induced adducts, UVC-induced cyclobutane pyrimidine dimers (CPD) inhibit initiation of DNA synthesis via Chk1 signaling (11). Therefore, we compared the S-phase checkpoint responses to BPDE and UVC-induced DNA damage.

We measured rates of [3H]-thymidine incorporation in H1299 cells at various times after treatment with two different doses of UVC. As shown in Fig. 8A, rates of DNA synthesis were reduced by 70% 2-4 hours after irradiation with 2.5 J/m² UVC, but recovered to control levels 8 hours post-treatment. In contrast, after high-dose (25 J/m²) UVC-treatment, rates of DNA synthesis...
were reduced to about 3% of control levels and did not recover. Therefore, the kinetics of inhibition and recovery of DNA synthesis in response to <100 nM BPDE and 2.5 J/m² UVC were very similar.

We determined the effect of UVC on Cdc25A levels and chromatin-association of Cdc45. As shown in Fig. 8B, treatments with 80 nM BPDE and 2.5 J/m² UVC both caused decreases in the levels of chromatin-bound Cdc45 but did not affect Cdc25A expression. Therefore, BPDE and UVC elicit similar checkpoint responses that target Cdc45 in a Cdc25A-independent manner.

We further determined whether BPDE and UVC elicit similar checkpoint responses in other cell lines. Therefore, H1299, A549 and Hela cells were treated with 80 nM BPDE or 2.5 J/m² UVC. As shown in Fig. 8B, these low doses of BPDE and UVC decreased the chromatin association of Cdc45 (concomitantly with Chk1 phosphorylation) and in a Cdc25A-independent manner in all three cell lines. Taken together, our data suggest that loss of chromatin-associated Cdc45 represents a general mechanism for the S-phase checkpoint induced by bulky lesions.

Discussion

Failure to properly integrate the biological responses after DNA damage and to accurately duplicate the human genome results in genetic instability, a hallmark of cancer (51,52). The BPDE-induced S-phase checkpoint is likely to be important for maintaining genomic stability and preventing cancer after B[a]P exposure. In this report we have investigated the molecular basis of the intra-S-phase checkpoint elicited by BPDE-adducted DNA. Earlier studies have suggested that Cdc25A/Cdk2 and Cdc7/Dbf4 represent targets of checkpoint signaling cascades triggered by DNA damage in S-phase (13,15,25,27,42). Therefore, we have tested roles for Cdc25A, Cdk2, and Cdc7/Dbf4 in responses to BPDE-induced DNA damage. Similar to previous studies from other labs that have used different genotoxins, we find that high doses of BPDE reduce Cdc25A levels, inhibit Cdk2 activity, and perturb association between Cdc7 and Dbf4. However, low concentrations of BPDE that inhibit initiation of DNA synthesis (i.e. activate the S-phase checkpoint) but do not affect global elongation, fail to elicit detectable changes in Cdc25A, Cdk2, or Cdc7-Dbf4 association. Consistent with this finding, we show that levels of Cdc25A, Cdk2, and Cdc7/Dbf4 are not rate-limiting for DNA synthesis when initiation is inhibited by low doses of BPDE. We suggest that Cdc25A, Cdk2, and Cdc7/Dbf4 are affected in response to global replication blocks (due to high levels of BPDE) or DNA DSBs (Fig. 9).

It is well-established that the S-phase checkpoint response to bulky adducts (such as those induced by BPDE and UV) is Chk1-mediated (4,11). It is also accepted that Chk1 is a negative regulator of Cdc25A stability and thus of Cdk2 activity (13). Therefore, it is surprising that the BPDE-induced (Chk1-mediated) inhibition of DNA synthesis occurs without changes in Cdk2 activity. One possible explanation is that inhibition of Cdc25A by Chk1 requires a critical threshold level (or duration) of Chk1 signaling that exceeds the transient and modest Chk1 response induced by low doses of BPDE. We previously showed that 600 nM BPDE induces a higher level and more sustained phosphorylation of Chk1 than is evident in cells treated with 60-100 nM BPDE (4). It is also possible that additional signaling events induced by high doses of BPDE contribute to Cdc25A downregulation. For example, we showed that Chk2 is phosphorylated in response to 600 nM BPDE, but not after treatment with 60 nM BPDE under conditions that activate the S-phase checkpoint. The DSB-induced intra-S-phase checkpoint involves Chk2-mediated amplification of Chk1-dependent systems (18). Therefore, efficient Cdc25A degradation might require threshold levels of adducts or different forms of DNA damage (i.e. DSBs) that elicit more extensive Chk1 and Chk2 signaling (Fig. 8).

In addition to Cdk2, Cdc7 kinase is crucial for initiation of DNA synthesis. Studies in model organisms have provided evidence that Cdc7 is a target of intra-S-phase checkpoint signaling (25). Using biochemical assays in Xenopus extracts, Gautier and colleagues showed that the association between Dbf4 and Cdc7 was perturbed in an ATR-dependent manner after etoposide treatment (27). Moreover, the addition of recombinant Dbf4
enabled DNA synthesis in etoposide-treated nuclei, demonstrating that Dbf4 was rate-limiting for DNA synthesis. It is unclear whether the concentrations of etoposide used in those experiments affected initiation or initiation and elongation steps of DNA synthesis. We have shown here that inhibition of initiation or elongation has no effect on Cdc7 levels or its chromatin association. However, inhibition of elongation after treatment with high concentrations of BPDE inhibits the association between Cdc7 and ectopically-expressed Dbf4. Unfortunately, due to the unavailability of antibodies, it has not been possible to perform similar experiments to determine the effect of S-phase checkpoint signaling on endogenous Dbf4 in human cells. However, antisera against murine Dbf4 are available, and in unpublished studies we have found that BPDE does not affect Dbf4 levels or its association with chromatin in mouse cell lines. Moreover, we have shown that ectopic expression of Dbf4 (alone or in combination with Cdc7) does not prevent inhibition of DNA synthesis in response to BPDE. Therefore, in contrast with etoposide-treated Xenopus nuclei, Dbf4 levels are not rate-limiting for DNA synthesis in BPDE-treated cells. Recent studies suggest that immuno-depletion of Dbf4 from Xenopus egg extracts fails to inhibit DNA synthesis (29,53). Therefore, Dbf4 may not be the sole target of S-phase checkpoint signaling in etoposide-treated Xenopus extracts.

Using replication-competent Xenopus extracts, Dunphy and colleagues have shown that Drf1, an alternative binding partner of Cdc7, associates with chromatin in response to agents that cause DNA damage and replication stress (28). Therefore, these workers suggested that Drf1 might be involved in S-phase checkpoint responses, and that its association with chromatin could provide a mechanism for S-phase inhibition. ASKL1a and ASKL1c are splice variants of the mammalian Drf1 homologue (54). We have tested the possible involvement of ASKL1a and ASKL1c in the S-phase checkpoint response to BPDE. In contrast with results from Xenopus extracts we find that endogenous, or over-expressed ASKL1a or ASKL1c do not associate with chromatin in response to DNA damage. Moreover, high level expression of ASKL1a or ASKL1c does not affect DNA synthesis in control or BPDE-treated cells (unpublished data).

Therefore, we find no evidence that Dbf4 and ASKL1 have major roles in the S-phase checkpoint in H1299 cells. However, it should be noted that we have focused on responses to low doses of a specific lesion (BPDE adducts), under conditions where replication initiation, but not elongation is blocked. It is unclear if the concentrations of genotoxins used in studies by the Dunphy and Gautier labs affected elongation. Moreover, it is probable that different forms of DNA damage signal via different checkpoint mechanisms. Further experiments will be necessary to determine if Dbf4 and ASKL1 are involved in S-phase checkpoint responses to other forms of DNA damage in mammalian cells.

Because our analyses of Cdk2 and Cdc7 did not support roles for these kinases as targets of the BPDE-induced S-phase checkpoint we have investigated other potential mechanisms that might account for the effect of low doses of BPDE on DNA synthesis. The sequence of events involved in initiation of DNA replication is well-understood. The assembly of pre-RCs (termed 'licensing') begins in telophase, and is completed after passage through G1. At the onset of S-phase, the actions of Cdk2 and Cdc7 result in recruitment of additional factors to the pre-RC. The first initiation factor recruited to the pre-RC is Mcm10. Mcm10 binding is necessary for recruitment of Cdc45 (45). Cdc45 in turn is required for origin unwinding and recruitment of replicative DNA polymerases (55). Cdc45 interacts with components of the pre-RC (including members of the Mcm2-7 complex, the putative replicative helicase) and DNA polymerases, thereby providing a physical bridge between initiation and elongation factors. We show here that BPDE inhibits the association of Cdc45 with chromatin concomitant with activation of the S-phase checkpoint. Chromatin association of other replication factors (including Mcm10) is unaffected by BPDE, possibly indicating that checkpoint signaling inhibits initiation of replication at a step distal to Mcm10 recruitment but prior to Cdc45 loading.
In our experiments, BPDE-induced S-phase checkpoint signaling reduced the levels of chromatin-associated Cdc45 without affecting the large soluble pool (which comprises ~90% of total cellular Cdc45). Therefore, it is unlikely that absolute levels of cellular Cdc45 are rate-limiting for DNA synthesis when the S-phase checkpoint is active. Indeed, Cdc45 over-expression did not abrogate the S-phase checkpoint (L.P.J. and C.V., data not shown). Instead, BPDE-induced S-phase checkpoint signaling most likely inhibits the recruitment of Cdc45 to pre-RCs, or stimulates dissociation of Cdc45 from pre-initiation complexes.

Cdc45 has been proposed to tether Polα to the replication complex during initiation via direct interactions with Mcm7 (47). The dissociation of Cdc45 from Mcm7 after BPDE treatment might provide a mechanism for negative regulation of initiation of DNA synthesis by DNA damage signaling. Our finding that the interaction of Cdc45 with a defined origin of replication (β-globin) is perturbed in BPDE-treated cells is also consistent with a role for Cdc45 as a target of DNA damage signaling during the S-phase checkpoint.

Although it is well known that Cdc45 loading requires Cdk2 (56), we show that inhibition of DNA synthesis by low doses of BPDE occurs in the absence of any changes in Cdk2 activity. Moreover, our over-expression studies show that Cdk2 activity is not rate-limiting for DNA synthesis in response to low doses of BPDE. Therefore, checkpoint signaling inhibits Cdc45 loading via a Cdk2-independent mechanism. Interestingly, there is a precedent for regulation of Cdc45 independent of changes in Cdk or Cdc7 activity. For example, in Xenopus extracts Cdc45 is loaded onto chromatin in a XMus101-dependent fashion that does not require pre-RC components or Mcm10 (57). The mammalian homologue of XMus101 is the checkpoint protein TopBP1, which is already known to be required for Chk1-mediated checkpoint signaling (58-60). However, the role of TopBP1 in regulating initiation of DNA synthesis or Cdc45 loading in mammalian cells has not yet been studied. It is possible that changes in TopBP1-dependent Cdc45 loading could account for the effects of BPDE that we observe. It has been reported that the protein phosphatase PP2A is also necessary for Cdc45 loading (61). Using Xenopus extracts, Walter and colleagues showed that ablation of PP2A inhibited chromatin loading of Cdc45 without affecting Cdk2 or Cdc7 (61). Interestingly, PP2A is already known to be negatively regulated by ATM pathway in response to IR (62). Potentially, a similar checkpoint-dependent inhibition of PP2A by the ATR/Chk1 pathway could provide a Cdk2/Cdc7-independent mechanism for inhibiting origin firing in response to low doses of BPDE.

In conclusion, we have demonstrated that Cdc45 is a likely target of the S-phase checkpoint induced by bulky lesions and that checkpoint-mediated inhibition of Cdc45-Mcm7 interactions occurs via a Cdk2-independent mechanism. Further studies are underway to determine the molecular basis for inhibition of Cdc45 by the S-phase checkpoint.

Acknowledgements

This work was supported by grants ES09558 and ES12917 from the NIH to C.V. and by Deutsche Forschungsgemeinschaft grant no. SFB604-B2 and Health Research Board Ireland grant no. RP/2003/133 to H. P. N. We thank Dr. Hisao Masai for providing expression vectors for Cdc7, Drf1, and Dbf4 and antisera against murine Dbf4. We thank Dr. Bill Kaufmann and Dr. Tim Heffernan for sharing unpublished results and for help and advice with the manuscript.
List of Figures

Fig. 1  Effect of ionizing radiation on DNA synthesis and Cdc25A levels in H1299 cells.

(A) Exponentially-growing H1299 cells were treated with 10 Gy of IR. At different time points after irradiation, rates of DNA synthesis were determined by measurements of [3H]-thymidine incorporation.

(B) Parallel cultures of control and irradiated H1299 cells were separated to give soluble and chromatin fractions as described under 'Materials and Methods'. The resulting protein extracts were separated by SDS-PAGE, transferred to nitrocellulose, and probed with antibodies against Cdc25A and Cdc45.

Fig. 2  Effect of BPDE on rates of DNA synthesis, Cdc25A levels and Cdk2 activity.

(A) Exponentially-growing H1299 cells were treated with 50 nM or 600 nM BPDE (or were left untreated for controls). At different time points after BPDE treatment, rates of DNA synthesis were determined by measurements of [3H]-thymidine incorporation (left panel). For the 4 hr time point, the size distribution of nascent DNAs was determined by velocity sedimentation (right panel).

(B) H1299 cells were lysed at different time points after treatment with 100 nM or 600 nM BPDE. The resulting cell extracts were analyzed for Cdc25A and phospho-Chk1 (Ser 317) by SDS-PAGE and immunoblotting. The band indicated by 'NS' represents a protein that was recognized non-specifically by the Chk1 antibody and which serves as a loading control.

(C) H1299 cells were infected with AdCon, with AdCyclin A + AdCdk2, or with Adp21. After 24 hrs, cells were treated with 100 nM BPDE or 600nM for 2 hrs, or were left untreated for controls. The cells were lysed and Cdk2 was immunoprecipitated from the extracts. The resulting immune complexes were assayed for kinase activity against purified histone as described under 'Materials and Methods'.

(D) H1299 cells were infected with AdCon, AdCdc25A, or AdCyclin A + AdCdk2 for 24 hrs. Adenovirus-mediated over-expression of Cdc25A, Cyclin A and Cdk2 was confirmed by immunoblotting of whole cell extracts (top). Control, Cdk2+Cyclin A, and Cdc25A-overexpressing cells were treated with 100 nM BPDE or were left untreated for controls. 2 hours later, rates of DNA synthesis were determined by [3H]-thymidine incorporation as described under 'Materials and Methods'.

Fig. 3  Effect of BPDE on association between Dbf4 and Cdc7.

Exponentially-growing H1299 cells were transiently transfected with CMV-GFP, or with CMV-FLAG-Dbf4 + CMV-Cdc7 as described under 'Materials and Methods'. Transfection efficiency was >90% as determined by immunofluorescence microscopy of GFP-transfected cultures. 48 hr post-transfection, cells were treated with 100 nM BPDE or 600 nM BPDE for 2 hrs (or were left untreated for controls). The resulting cells were lysed and normalized for protein concentration. An aliquot of each lysate was saved for analysis ('Input' fraction). The remainder of each extract was immunoprecipitated (IP) with anti-FLAG antibodies. The resulting immune complexes were resolved on SDS-PAGE. Co-immunoprecipitated Cdc7 present in the anti-FLAG complexes was detected by SDS-PAGE and immunoblotting (IB).

Fig. 4  Effect of BPDE on chromatin-association of DNA replication factors.

(A) H1299 cells were infected with AdCon or AdCdt1 for 24hrs. The resulting cultures were separated into soluble and chromatin fractions. Washed chromatin fractions were separated by SDS-PAGE and
analyzed for levels of Cdc45 and Mcm10 by immunoblotting. 'NS' represents a non-specific protein band recognized by the Mcm10 antibody and serves as a loading control.

(B) H1299 cells were treated with 60 nM BPDE or 600 nM BPDE. At 0, 2, 5, and 8 hrs after BPDE treatment cells were separated into soluble and chromatin fractions. After normalizing for protein, extracts were separated by SDS-PAGE and analyzed for levels of phospho-Chk1 (soluble fraction), phospho-Chk2 (soluble fraction), Cdc45 (chromatin and soluble fractions), and Mcm10, Mcm7, and PCNA (chromatin fractions) as described under 'Materials and Methods'.

(C) H1299 cells were transfected with non-targeting control siRNA or Chk1 siRNA. 48 hours later, cells were treated with 80 nM BPDE (or were left untreated for controls). After 2 hours, the resulting cultures were separated into soluble and chromatin fractions. Chk1 and Cdc45 levels were detected by immunoblotting.

Fig. 5 Effect of BPDE on the interaction between Cdc45 and Mcm7.

(A) H1299 cells were treated with 600 nM BPDE for 4 hr, or were left untreated for controls. The resulting cells were separated into soluble and chromatin fractions. After normalizing for protein content, chromatin fractions were digested with DNase I to release chromatin-associated proteins. The DNase-solubilized chromatin fractions were immunoprecipitated with anti-Mcm7 or with a control IgG. Immune complexes were resolved by SDS-PAGE, transferred to nitrocellulose, and probed sequentially with antibodies against Mcm7 and Cdc45.

(B - C) H1299 cells were treated with 60 nM or 600 nM BPDE. At 0, 2, 4, and 8 hrs after BPDE treatment cells were separated into soluble and chromatin fractions. Chromatin-associated proteins were solubilized using DNAse-treatment. Then, DNAse-released (B) and soluble (C) proteins were immunoprecipitated (IP) with anti-Mcm7 antibodies. The resulting immune complexes were resolved by SDS-PAGE, transferred to nitrocellulose, and probed sequentially with antibodies against Cdc45, Mcm7 and Rb. IB, immunoblotting.

(D) H1299 cells were treated with 100 nM UCN-01 for 1 hr, or were left untreated. Then, control and UCN-01-treated cells received 60 nM BPDE or 600 nM BPDE for 0, 4, and 8 hours. Chromatin fractions from the cells were harvested and digested with DNase I. Solubilized chromatin proteins were immunoprecipitated (IP) with an antibody against Mcm7. The resulting immunoprecipitates were resolved by SDS-PAGE, transferred to nitrocellulose and probed with anti-Cdc45 or anti-Mcm7 as indicated. IB, immunoblotting.

Fig. 6 ChIP analysis of association between Cdc45 and the β-globin locus.

(A) H1299 cells were treated with 0 nM, 100 nM BPDE or 600 nM BPDE as indicated for 2 hrs. Cells were treated briefly with formaldehyde to cross-link DNA-protein complexes prior to harvest. Chromatin was extracted from the formaldehyde-treated cultures, and sonicated to generate 1-2 kb fragments as described under 'Materials and Methods'. The resulting chromatin was analyzed by PCR directly using primers designed to amplify a portion of the β-globin origin ('Input'), or was immunoprecipitated (IP) with anti-Cdc45 (or with a non-specific IgG as a negative control) prior to PCR analysis. PCR products were separated on a 1% agarose gel and visualized using ethidium bromide.

(B) H1299 cells were treated with 5 mM caffeine or 100 nM UCN-01 for 1 hr, or were left untreated for controls. Some of the resulting cultures were given 100 nM BPDE for an additional 2 hrs. Chromatin
was extracted from formaldehyde-fixed cells and used in ChIP assays to detect association between Cdc45 and the β-globin locus exactly as described for Fig. 6 (A).

**Fig. 7 Effect of BPDE and Chk1 on Cdc45-induced chromatin decondensation.**

(A) A03_1 cells were treated with 60 nM BPDE and / or 150 nM UCN-01 as indicated. 2 hours after treatments, rates of DNA synthesis were determined by measurements of [3H]-thymidine incorporation.

(B) In an experiment conducted in parallel with the DNA synthesis assays shown in Fig. 7A, control and BPDE-treated cells were lysed and analyzed for Cdc25A levels by immunoblotting.

(C) A03_1 cells growing exponentially on glass slides were transiently transfected with expression plasmids encoding LacI or LacI-Cdc45. In parallel cultures, cells were co-transfected with an expression vector for Chk1. 24 hr post-transfection, some cultures were treated with 100 nM BPDE for 2 hrs prior to fixing with formaldehyde. The fixed cells were stained with anti-Lac1 antisera and visualized by immunofluorescence microscopy as described under 'Materials and Methods'. Representative cells exhibiting BPDE- and Chk1-induced changes in chromatin condensation are shown.

(D) Cells containing condensed, decondensed, and indeterminate chromatin at the lacO/DHFR locus were enumerated. 200 cells were examined for each experimental condition.

**Fig. 8 Effect of UVC-treatment on DNA synthesis, Cdc25A levels, and chromatin-association of Cdc45.**

(A) H1299 cells were irradiated with 2.5 or 25 J/m² UVC (or were left untreated for controls). At different time points after UVC treatment, rates of DNA synthesis were determined by measurements of [3H]-thymidine incorporation.

(B) H1299, A549 and Hela cells were treated with 80 nM BPDE or 2.5 J/m² UVC. 2 hours later, the resulting cells were separated into soluble and chromatin fractions. After normalizing for protein content, the levels of Cdc25A, phospho-Chk1 (Ser 317), Cdc45 and PCNA were detected by immunoblotting.

**Fig. 9 Model for distinct mechanisms of Cdc45 regulation in response to low and high levels of BPDE adducts and ionizing radiation-induced DSBs.**

Low levels of BPDE adducts inhibit Cdc45 loading in a Chk1-dependent manner that does not involve changes in Cdc25A and Cdk2. In contrast, high levels of DNA adducts that cause global replication blocks, or ionizing radiation-induced DSBs activate Chk1 and Chk2, and target Cdc25A for degradation. The resulting inhibition of Cdk2 activity prevents Cdc45 loading at unfired origins.
References

Fig. 1

A

Rate of DNA Synthesis (% Control)

Time after IR (hr)

B

hrs after IR: 0 .5 1 2 4 8

Cdc25A Remaining (%): 100 105 111 22 6 8

Cdc45 Remaining (%): 100 34 42 27 31 31

Cdc25A (Soluble) →
Cdc45 (Nuclear) →
Cdc45 (Soluble) →
### Fig. 3

<table>
<thead>
<tr>
<th>BPDE (nM):</th>
<th>Control</th>
<th>GFP</th>
<th>FLAG-Dbf4 + Cdc7</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>100</td>
<td>600</td>
<td>100</td>
<td>600</td>
</tr>
</tbody>
</table>

**Input:**
- Cdc7

**FLAG IP, FLAG IB:**
- FLAG-Dbf4

**FLAG IP, Cdc7 IB:**
- Cdc7
Fig. 4

A

B

C

BPDE (60nM):

<table>
<thead>
<tr>
<th></th>
<th>siCon</th>
<th>siChk1</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Chk1

Cdc45 (Soluble)

Cdc45 (Chromatin)
Fig. 5

A

<table>
<thead>
<tr>
<th>BPDE:</th>
<th>IgG Control</th>
<th>α-Mcm7</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Mcm7 (Chromatin)
- Cdc45 (Chromatin)
- Heavy Chain

B

<table>
<thead>
<tr>
<th>Hrs after BPDE:</th>
<th>60 nM BPDE</th>
<th>600 nM BPDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>4</td>
<td>56</td>
</tr>
<tr>
<td>2</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>4</td>
<td>41</td>
<td>39</td>
</tr>
<tr>
<td>8</td>
<td>30</td>
<td>42</td>
</tr>
</tbody>
</table>

- Mcm7 (Chromatin)
- Cdc45 (Chromatin)
- Rb (Chromatin)

C

<table>
<thead>
<tr>
<th>Hrs after BPDE:</th>
<th>60 nM BPDE</th>
<th>600 nM BPDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>2</td>
<td>41</td>
<td>39</td>
</tr>
<tr>
<td>4</td>
<td>30</td>
<td>42</td>
</tr>
<tr>
<td>8</td>
<td>56</td>
<td>58</td>
</tr>
</tbody>
</table>

- Mcm7 (Soluble)
- Cdc45 (Soluble)
- Rb (Soluble)

D

<table>
<thead>
<tr>
<th>Hrs after 60 nM BPDE:</th>
<th>- UCN-01</th>
<th>+ UCN-01</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>4</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>8</td>
<td>105</td>
<td>103</td>
</tr>
</tbody>
</table>

- Mcm7 (Chromatin)
- Cdc45 (Chromatin)

<table>
<thead>
<tr>
<th>Hrs after 600 nM BPDE:</th>
<th>- UCN-01</th>
<th>+ UCN-01</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>4</td>
<td>31</td>
<td>31</td>
</tr>
<tr>
<td>8</td>
<td>5</td>
<td>5</td>
</tr>
</tbody>
</table>

- Mcm7 (Chromatin)
- Cdc45 (Chromatin)
Fig. 6

A

B

β-Globin PCR product

β-Globin PCR product
Fig. 8

A

Rate of DNA Synthesis (% Control) vs. Time After UVC (hr)

- 2.5 J/m²
- 25 J/m²

B

<table>
<thead>
<tr>
<th></th>
<th>H1299</th>
<th>A549</th>
<th>HeLa</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPDE (80nM):</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>UVC (2.5 J/m²):</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

- Cdc25A
- P-Chk1
- Cdc45 (chromatin)
- PCNA (chromatin)
The Chk1-mediated S-phase checkpoint targets initiation factor Cdc45 via a Cdc25a/Cdk2-independent mechanism
Peijun Liu, Laura R. Barkley, Tovah Day, Xiaohui Bi, Damien M. Slater, Mark G. Alexandrow, Heinz-Peter Nasheuer and Cyrus Vaziri

J. Biol. Chem. published online August 15, 2006

Access the most updated version of this article at doi: 10.1074/jbc.M602982200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts